Compare Quest Diagnostics Inc (DGX) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Gap Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Gap Inc trades at $23.33 (market cap $8.29B). The key difference: Quest Diagnostics Inc is far larger — about 3× Gap Inc's market cap, and Gap Inc pays the higher dividend (2.96%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Gap Inc for 37 Days on average.
| DGX | GAP | |
|---|---|---|
Market Cap | $25.06B | $8.29B |
Volume | 927,361 | 5,470,564 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $29.13 |
52-Week Low | $173.49 | $18.35 |
Typical Hold Time | 56 Days | 37 Days |
Enterprise Value | $30.82B | $11.53B |
Dividend Yield | 1.52% | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Gap (GAP) trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.11 and robust profitability, including a 33.78% ROE. Recent earnings beat estimates in Q1 and Q2 2026, and the company is expanding into music partnerships to engage customers. Cash flow from operations remains healthy at $1.49 billion for 2025.
The outlook is positive given Gap's attractive valuation, earnings momentum, and strategic initiatives. Key risks include competitive pressures in retail and reliance on brand revitalization. Analyst consensus is a $25.67 price target, suggesting upside potential, but investors should monitor execution of growth strategies amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
